| 1 |
35416588 | Mortality in People with Type 2 Diabetes Following SARS-CoV-2 Infection: A Population Level Analysis of Potential Risk Factors. | 2022 May |
2 |
| 2 |
35455439 | A Clinical Perspective of the Multifaceted Mechanism of Metformin in Diabetes, Infections, Cognitive Dysfunction, and Cancer. | 2022 Apr 2 |
1 |
| 3 |
35558742 | Different Interactive Effects of Metformin and Acarbose With Dietary Macronutrient Intakes on Patients With Type 2 Diabetes Mellitus: Novel Findings From the MARCH Randomized Trial in China. | 2022 |
3 |
| 4 |
32770520 | Metformin Lowers Body Weight But Fails to Increase Insulin Sensitivity in Chronic Heart Failure Patients without Diabetes: a Randomized, Double-Blind, Placebo-Controlled Study. | 2021 Jun |
1 |
| 5 |
33527807 | Clinical Evidence of Evogliptin plus Metformin in Management of Type 2 Diabetes mellitus. | 2021 Feb |
1 |
| 6 |
33881795 | Ambulatory noninsulin treatment of type 2 diabetes mellitus in the United States, 2015 to 2019. | 2021 Aug |
2 |
| 7 |
34135015 | Effect of Medical and Surgical Interventions on α-Cell Function in Dysglycemic Youth and Adults in the RISE Study. | 2021 Sep |
3 |
| 8 |
34705249 | Glucagon-like Peptide-1 Receptor Agonists and Cardioprotective Benefit in Patients with Type 2 Diabetes Without Baseline Metformin: A Systematic Review and Update Meta-analysis. | 2021 Nov |
1 |
| 9 |
32274915 | Metabolic syndrome in children. | 2020 Aug |
1 |
| 10 |
32690574 | Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies. | 2020 Jul |
1 |
| 11 |
32700188 | Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK. | 2020 Sep |
1 |
| 12 |
33269063 | Factors associated with improvement in waist-to-height ratio among newly diagnosed type 2 diabetes patients treated with acarbose or metformin: A randomized clinical trial study. | 2020 Nov 15 |
1 |
| 13 |
30615231 | Metformin attenuates the postprandial fall in blood pressure in type 2 diabetes. | 2019 May |
2 |
| 14 |
30767126 | Cardiovascular Protection with Anti-hyperglycemic Agents. | 2019 Jun |
1 |
| 15 |
31439934 | Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. | 2019 Oct |
1 |
| 16 |
31705902 | Pharmacology of metformin - An update. | 2019 Dec 15 |
1 |
| 17 |
29326107 | TCF7L2 Genetic Variation Augments Incretin Resistance and Influences Response to a Sulfonylurea and Metformin: The Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH). | 2018 Mar |
2 |
| 18 |
29516618 | Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England. | 2018 Jul |
2 |
| 19 |
29559078 | [Metformin is a possible glucagon-like peptide 1 stimulator]. | 2018 Mar 19 |
1 |
| 20 |
30084684 | GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES: A COMPREHENSIVE REVIEW OF HOW TO WEIGH THE OPTIONS, SELECT THE RIGHT PATIENTS, AND MAXIMIZE BENEFITS. | 2018 Aug 7 |
1 |
| 21 |
30518693 | Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes. | 2018 Dec 6 |
10 |
| 22 |
30815546 | Gut microbiome differences between metformin- and liraglutide-treated T2DM subjects. | 2018 Jan |
1 |
| 23 |
27717194 | Associations between changes in glucagon-like peptide-1 and bodyweight reduction in patients receiving acarbose or metformin treatment. | 2017 Aug |
1 |
| 24 |
27761984 | Metformin reduces the rate of small intestinal glucose absorption in type 2 diabetes. | 2017 Feb |
5 |
| 25 |
27862873 | Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes. | 2017 Mar |
1 |
| 26 |
28276972 | Pharmacotherapy of 'treatment resistant' type 2 diabetes. | 2017 Apr |
1 |
| 27 |
28321905 | Differential increments of basal glucagon-like-1 peptide concentration among SLC47A1 rs2289669 genotypes were associated with inter-individual variability in glycaemic response to metformin in Chinese people with newly diagnosed Type 2 diabetes. | 2017 Jul |
1 |
| 28 |
28432082 | Effect of oral contraceptives and/or metformin on GLP-1 secretion and reactive hypoglycaemia in polycystic ovary syndrome. | 2017 May |
3 |
| 29 |
28938439 | Single-Dose Metformin Enhances Bile Acid-Induced Glucagon-Like Peptide-1 Secretion in Patients With Type 2 Diabetes. | 2017 Nov 1 |
3 |
| 30 |
26331290 | Efficacy of acarbose and metformin in newly diagnosed type 2 diabetes patients stratified by HbA1c levels. | 2016 Jul |
2 |
| 31 |
26381272 | Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies. | 2016 Feb |
1 |
| 32 |
27003305 | Cholecystokinin-Induced Gallbladder Emptying and Metformin Elicit Additive Glucagon-Like Peptide-1 Responses. | 2016 May |
4 |
| 33 |
27265206 | Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metformin. | 2016 Oct |
17 |
| 34 |
27426125 | Gut-Brain Axis and Metabolism in Polycystic Ovary Syndrome. | 2016 |
1 |
| 35 |
27780736 | Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin. | 2016 Dec |
4 |
| 36 |
25678952 | Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus. | 2015 Feb |
1 |
| 37 |
26480664 | [Effects of GLP-1 Agonist Exenatide on Cardiac Diastolic Function and Vascular Endothelial Function in Diabetic Patients]. | 2015 Jul |
1 |
| 38 |
23668534 | Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence. | 2014 Feb |
2 |
| 39 |
24186866 | Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose. | 2014 Feb |
1 |
| 40 |
24627290 | Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects. | 2014 Jun |
1 |
| 41 |
24647737 | Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin. | 2014 Aug |
1 |
| 42 |
24699248 | Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies. | 2014 |
2 |
| 43 |
24827939 | Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study. | 2014 Oct |
2 |
| 44 |
24988476 | Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. | 2014 |
1 |
| 45 |
25089625 | Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies. | 2014 |
2 |
| 46 |
25213800 | Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in sweden. | 2014 Dec |
1 |
| 47 |
20455069 | Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells. | 2012 Dec |
2 |
| 48 |
22486277 | Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus. | 2012 Aug |
4 |
| 49 |
20152998 | Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus. | 2011 Jan |
8 |
| 50 |
21199262 | Pharmacological management of type 2 diabetes: the potential of incretin-based therapies. | 2011 Feb |
2 |